Literature DB >> 17335682

Hepatitis C and HIV.

Jenny O Smith1, Richard K Sterling.   

Abstract

HIV and hepatitis C virus (HCV) are global health concerns, and coinfection with these viruses is common due to shared routes of transmission. Mortality rates from AIDS and HIV-associated opportunistic infections have decreased since the institution of highly active antiretroviral therapy, but the incidence of liver-related mortality in coinfected patients has subsequently risen significantly. This increase in progression of liver disease and its subsequent increased mortality have spurred research into the optimization of evaluation and management of the HIV-HCV coinfected patient.

Entities:  

Mesh:

Year:  2007        PMID: 17335682     DOI: 10.1007/s11894-008-0025-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  43 in total

Review 1.  [Hepatitis C virus and human immunodeficiency virus co-infection].

Authors:  S Pol
Journal:  Gastroenterol Clin Biol       Date:  2001-04

Review 2.  Care of patients with hepatitis C and HIV co-infection.

Authors:  Vincent Soriano; Massimo Puoti; Mark Sulkowski; Stefan Mauss; Patrice Cacoub; Antonietta Cargnel; Douglas Dieterich; Angelos Hatzakis; Jurgen Rockstroh
Journal:  AIDS       Date:  2004-01-02       Impact factor: 4.177

Review 3.  Hepatitis B or hepatitis C and human immunodeficiency virus infection.

Authors:  Robert Thimme; Hans Christian Spangenberg; Hubert E Blum
Journal:  J Hepatol       Date:  2005-01-28       Impact factor: 25.083

4.  The long-term pathological evolution of chronic hepatitis C.

Authors:  M Yano; H Kumada; M Kage; K Ikeda; K Shimamatsu; O Inoue; E Hashimoto; J H Lefkowitch; J Ludwig; K Okuda
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

5.  Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.

Authors:  Thomas B Kelleher; Shruti H Mehta; Ramakrishnan Bhaskar; Mark Sulkowski; Jacquie Astemborski; David L Thomas; Richard E Moore; Nezam H Afdhal
Journal:  J Hepatol       Date:  2005-04-25       Impact factor: 25.083

6.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

Authors:  Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren
Journal:  J Infect Dis       Date:  2005-08-11       Impact factor: 5.226

7.  Hepatitis C and progression of HIV disease.

Authors:  Mark S Sulkowski; Richard D Moore; Shruti H Mehta; Richard E Chaisson; David L Thomas
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

8.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

9.  Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.

Authors:  David M Moore; Robert S Hogg; Paula Braitstein; Evan Wood; Benito Yip; Julio S G Montaner
Journal:  Antivir Ther       Date:  2006

10.  Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study.

Authors:  Katie B Anderson; Jodie L Guest; David Rimland
Journal:  Clin Infect Dis       Date:  2004-10-25       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.